Q4FY23 Results
The drug maker has reported a drop of more than 25% sequentially in consolidated PAT which is attributable to owners in the March 2023 quarter. However, Q4 PAT was better on a year-on-year basis on the back of strong EBITDA growth and higher revenue.
Revenue from operations stood at ₹4,330.30 crore in Q4FY23, rising by 12% from ₹3,864.50 crore in the same quarter a year ago. However, revenue was up by 2.02% from ₹4,244.56 crore in Q3FY23.
- India is back to double-digit growth after a tepid last year. Europe, Middle East, and Africa Sales up 11% in Q4. America is doing 175-180 million$
- Margin improved from 6.9% to 13% on a YoY basis
- Other Income: They are getting some funds from the government in the form of the PLI scheme. Mgmt is confident that it would be sustainable for the coming few quarters.
- Management guided for an 18% margin going forward from the current 13%
- Mgmt is confident of launching the Spiriva generic by July-August in the US market. It’s a medicine to treat asthma and thus comes in the chronic section.
- Diabetes medicine is still a struggle as they lost exclusivity for one therapy.
- Gastrointestinal, women’s health performing well in India.
- Brazil and American subsidiaries are currently loss-making.
Looks like the stock is finally on track and couldn’t find any negative, their guidance of 18% is quite impressive
| Subscribe To Our Free Newsletter |
